insights_auto
Prečo akcie 22UA klesli 2,42%?
Preskúmať podrobnejšiechevron_right
22UA:ETR
BioNTech
78,60 €
arrow_downward
-2,42%(-1,95) 1 d.
16. 10., 17:35:51 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre 22UA…
Otvoriť
80,75 €
Vysoká
81,15 €
Nízka
78,40 €
Trh. kap.
22,03 mld.
Priem. obj.
26,41 tis.
Objem
12,88 tis.
Max. za 52 týž.
105,70 €
Min. za 52 týž.
68,30 €
Počet zamestnancov
8 tis.
Otvoriť
80,75 €
Vysoká
81,15 €
Nízka
78,40 €
Trh. kap.
22,03 mld.
Priem. obj.
26,41 tis.
Objem
12,88 tis.
Max. za 52 týž.
105,70 €
Min. za 52 týž.
68,30 €
Počet zamestnancov
8 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
24/7 Wall St.
·
pred 17 hodinami
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Pluang
·
pred 2 dňami
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
pred 3 dňami
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
Profil
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Informácie o subjekte BioNTech